Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Timo_Lappalainen
|
| gptkbp:country |
gptkb:Finland
|
| gptkbp:focusArea |
animal health
oncology respiratory diseases central nervous system disorders |
| gptkbp:founded |
1917
|
| gptkbp:headquarters_location |
gptkb:Espoo
|
| https://www.w3.org/2000/01/rdf-schema#label |
Orion Pharma
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:numberOfEmployees |
~3500
|
| gptkbp:parentCompany |
gptkb:Orion_Corporation
|
| gptkbp:products |
prescription drugs
generic medicines self-care products |
| gptkbp:revenue |
over €1 billion (2022)
|
| gptkbp:stockExchange |
gptkb:Helsinki_Stock_Exchange
|
| gptkbp:website |
https://www.orion.fi/en/
|
| gptkbp:bfsParent |
gptkb:Orion_Corporation
|
| gptkbp:bfsLayer |
6
|